afa-281
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2023 (NCT05547503)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06649747 | Phase 2 | Aug 1, 2026 | Afasci Inc |
| NCT06710431 | Phase 2 | Oct 1, 2025 | Afasci Inc, University of California, Los Angeles |
| NCT06719908 | Phase 1 | Jul 1, 2025 | Afasci Inc |
| NCT05547503 | Phase 1 | Jan 31, 2023 | Afasci Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Afasci Inc | For profit | 4 | 4 | 2 | 2023 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1